Sanghoon Lee, Ph.D, M.S.

Peer-Reviewed Articles

1. Guo S, Liu X, Cheng X, Jiang Y, Ji S, Liang Q, Koval A, Li Y, Owen LA, Kim IK, Aparicio A, Lee S, Sood AK, Kopetz S, Shen JP, Weinstein JN, DeAngelis MM, Chen R, Wang W. A deconvolution framework that uses single-cell sequencing plus a small benchmark dataset for accurate analysis of cell-type ratios in complex tissue samples. Genome Res. e-Pub 2024. PMID: 39586714.
2. Kim MS, Glassman D, Handley KF, Lankenau Ahumada A, Jennings NB, Bayraktar E, Foster K, Joseph R, Lee S, Coleman RL, Sood AK. Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Med 13(15):e70031, 2024. PMID: 39114948.
3. How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med. e-Pub 2024. PMID: 39151421.
4. Corvigno S, Liu Y, Bayraktar E, Stur E, Bayram NN, Ahumada AL, Nagaraju S, Rodriguez-Aguayo C, Chen H, Vu TC, Wen Y, Liang H, Zhao L, Lee S, Lopez-Berestein G, Sood AK. Enhanced plant-derived vesicles for nucleotide delivery for cancer therapy. NPJ Precis Oncol 8(1):86, 2024. e-Pub 2024. PMID: 38582949.
5. Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen Y, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee S, Eberlin LS, Sood AK. In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy. NPJ Precis Oncol 115(1):115, 2023. e-Pub 2023. PMID: 37923835.
6. Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, Lawson BC, Burns KH, Lee S, Westin SN, Moiso E, Williams MJ, Bardhan NM, Pisanic T, Matulonis U, Weigelt B, Shih I, Konstantinopoulos PA, Gaillard S, Wang L, Aghajanian C, D'Andrea AD, Hammond P, Shah S, Wucherpfennig KW, Lu KH. Transforming Ovarian Cancer Care by Targeting Minimal Residual Disease. Med 4(11):750-760, 2023. PMID: 37951209.
7. Foster KI, Shaw KRM, Jin J, Westin SN, Yap TA, Glassman DM, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Liu Y, Fleming ND, Sood AK. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer 129(11):1672-1680, 2023. e-Pub 2023. PMID: 36930815.
8. Glassman D, Kim MS, Spradlin M, Badal S, Taki M, Bhattacharya P, Dutta P, Kingsley CV, Foster KI, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, Wuchu F, Bayraktar E, Wu Y, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin LS, Nagrath D, Sood AK. Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience 26(2):106020, 2023. e-Pub 2023. PMID: 36824283.
9. Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC, Fleming ND, Conrads TP, Sood AK. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open 5(10):e2236626, 2022. e-Pub 2022. PMID: 36239936.
10. Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MC. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer 3(10):1211-1227, 2022. e-Pub 2022. PMID: 36253486.
11. Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK. Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation. Clin Cancer Res 28(17):3669-3676, 2022. e-Pub 2022. PMID: 35736816.
12. Zhao L, Corvigno S, Ma S, Celestino J, Fleming ND, Hajek RA, Lankenau Ahumada A, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee S. Molecular profiles of serum-derived extracellular vesicles in high-grade serous ovarian cancer. Cancers (Basel) 14(15):3589, 2022. e-Pub 2022. PMID: 35892848.
13. Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT. Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. NPJ Breast Cancer 8(1):64, 2022. e-Pub 2022. PMID: 35538088.
14. Stur E, Corvigno S, Xu M, Chen K, Tan Y, Lee S, Liu J, Ricco E, Kraushaar D, Castro P, Zhang J, Sood AK. Spatially resolved transcriptomics of high-grade serous ovarian carcinoma. iScience 25(3):103923, 2022. e-Pub 2022. PMID: 35252817.
15. Glassman D, Bateman NW, Lee S, Zhao L, Yao J, Tan Y, Ivan C, Rangel KM, Zhang J, Conrads KA, Hood BL, Abulez T, Futreal PA, Fleming ND, Afshar-Kharghan V, Maxwell GL, Conrads TP, Chen K, Sood AK. Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers (Basel) 14(6), 2022. e-Pub 2022. PMID: 35326647.
16. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clin Cancer Res 27(23):6345, 2021. e-Pub 2021. PMID: 34518313.
17. Lobo de Figueiredo-Pontes L, Adamcova MK, Grusanovic S, Kuzmina M, Aparecida Lopes I, Fernandes de Oliveira Costa A, Zhang H, Strnad H, Lee S, Moudra A, Jonasova AT, Zidka M, Welner RS, Tenen DG, Alberich-Jorda M. Improved hematopoietic stem cell transplantation upon inhibition of natural killer cell-derived interferon gamma. Stem Cell Reports 16(8):1999-2013, 2021. e-Pub 2021. PMID: 34242616.
18. Ma S, Mangala LS, Hu W, Bayaktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar-Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL, Sood AK. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep 36(7):109549, 2021. PMID: 34407412.
19. Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings NB, Liu J, Lopez-Berestein G, Ram P, Sood AK. Gain-of-Function p53 Protein Transferred via Small Extracellular Vesicles Promotes Conversion of Fibroblasts to a Cancer-Associated Phenotype. Cell Rep 34(6):108726, 2021. PMID: 33567287.
20. Lee S*, Zhao L, Little LD, Westin SN, Jazarei AA, Fleming ND, Zhang J, Futreal PA, Sood AK*. Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. iScience 24(2):102053, 2021. e-Pub 2021. PMID: 33537658.
21. Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming ND. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel) 13(4), 2021. e-Pub 2021. PMID: 33572451.
22. Zhou Q, Yu M, Tirado-Magallanes R, Li B, Kong L, Guo M, Tan ZH, Lee S, Chai L, Numata A, Benoukraf T, Fullwood MJ, Osato M, Ren B, Tenen DG. ZNF143 mediates CTCF-bound promoter-enhancer loops required for murine hematopoietic stem and progenitor cell function. Nat Commun 12(1):43, 2021. e-Pub 2021. PMID: 33397967.
23. Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer. Mol Cancer Ther 19(11):2396, 2020. e-Pub 2020. PMID: 32943548.
24. Chu Y, Awasthi A, Lee S, Edani D, Yin C, Hochberg J, Shah T, Chung TH, Ayello J, van de Ven C, Klein C, Lee D, Cairo MS. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget 11(32):3035-3047, 2020. e-Pub 2020. PMID: 32850008.
25. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular analysis of clinically defined subsets of high-grade serous ovarian cancer. Cell Rep 31(2):107502, 2020. e-Pub 2020. PMID: 32294438.
26. Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol 155(3):420-428, 2019. e-Pub 2019. PMID: 31623857.
27. Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy. Cancer Cell 35(6):851-867, 2019. PMID: 31185210.
28. Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget 10(37):3533-3546, 2019. e-Pub 2019. PMID: 31191824.
29. Chu Y*, Lee S*, Shah T, Yin C, Barth M, Miles RR, Ayello J, Morris E, Harrison L, Van de Ven C, Galardy P, Goldman SC, Lim MS, Hermiston M, McAllister-Lucas LM, Giulino-Roth L, Perkins SL, Cairo MS. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. Oncoimmunology 8(2):e1512455, 2019. e-Pub 2018. PMID: 30546948.
30. Kardosova M, Zjablovskaja P, Danek P, Angelisova P, de Figueiredo-Pontes LL, Welner RS, Brdicka T, Lee S, Tenen DG, Alberich-Jorda M. C/EBPγ is dispensable for steady-state and emergency granulopoiesis. Haematologica 103(8):e331-e335, 2018. e-Pub 2018. PMID: 29567783.
31. Lee S, Shah T, Yin C, Hochberg J, Ayello J, Morris E, van de Ven C, Cairo MS. Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. Oncotarget 9(11):9776-9788, 2018. e-Pub 2018. PMID: 29515770.
32. Lee S, Day NS, Miles RR, Perkins SL, Lim MS, Ayello J, van de Ven C, Harrison L, El-Mallawany NK, Goldman S, Cairo MS. Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. Br J Haematol 177(4):601-611, 2017. e-Pub 2017. PMID: 28474336.
33. Lee S, Luo W, Shah T, Yin C, O'Connell T, Chung TH, Perkins SL, Miles RR, Ayello J, Morris E, Harrison L, van de Ven C, Cairo MS. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL. Oncotarget 8(17):27839-27853, 2017. PMID: 28427156.
34. Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Wong KF, Lee S, Ravikumar S, Srivastava S, Tian X, Poon RT, Fan ST, Luk JM, Dan YY, Salto-Tellez M, Chai L, Tenen DG. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 368(24):2266-76, 2013. PMID: 23758232.
35. Staber PB, Zhang P, Ye M, Welner RS, Nombela-Arrieta C, Bach C, Kerenyi M, Bartholdy BA, Zhang H, Alberich-Jordà M, Lee S, Yang H, Ng F, Zhang J, Leddin M, Silberstein LE, Hoefler G, Orkin SH, Göttgens B, Rosenbauer F, Huang G, Tenen DG. Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells. Mol Cell 49(5):934-46, 2013. e-Pub 2013. PMID: 23395001.
36. Levantini E, Lee S, Radomska HS, Hetherington CJ, Alberich-Jorda M, Amabile G, Zhang P, Gonzalez DA, Zhang J, Basseres DS, Wilson NK, Koschmieder S, Huang G, Zhang DE, Ebralidze AK, Bonifer C, Okuno Y, Gottgens B, Tenen DG. RUNX1 regulates the CD34 gene in haematopoietic stem cells by mediating interactions with a distal regulatory element. EMBO J 30(19):4059-70, 2011. e-Pub 2011. PMID: 21873977.
37. Zhou YD, Lee S, Jin Z, Wright M, Smith SE, Anderson MP. Arrested Maturation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy. Nat Med 15(10):1208-1214, 2009. e-Pub 2009. PMID: 19701204.
38. Ebralidze AK, Guibal FC, Steidl U, Zhang P, Lee S, Bartholdy B, Jorda MA, Petkova V, Rosenbauer F, Huang G, Dayaram T, Klupp J, O'Brien KB, Will B, Hoogenkamp M, Borden KL, Bonifer C, Tenen DG. PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. Genes Dev 22(15):2085-2092, 2008. PMID: 18676813.
39. Lee S, Huang H, Niu Y, Tommasino M, Lenoir G, Sylla BS. Dok1 expression and mutation in Burkitt's lymphoma cell lines. Cancer Lett 245(1-2):44-50, 2007. e-Pub 2005. PMID: 16338067.
40. Lee S, Andrieu C, Saltel F, Destaing O, Auclair J, Pouchkine V, Michelon J, Salaun B, Kobayashi R, Jurdic P, Kieff ED, Sylla BS. IkappaB kinase beta phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation. Proc Natl Acad Sci U S A 101(50):17416-21, 2004. e-Pub 2004. PMID: 15574499.
41. Lee S, Roy F, Galmarini CM, Accardi R, Michelon J, Viller A, Cros E, Dumontet C, Sylla BS. Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia. Oncogene 23(13):2287-97, 2004. PMID: 14730347.
42. Yoo SL, Sang SC, SH Ryoo, S Lee, TH Lee and DY Yu. Sequence Analysis of β-lactoglobulin Promoter in Korean Cattle. Journal of Animal Science & Technology 42(4):443-450, 2000.
43. Sang BC, JA Kim, S Lee, GW Seo and SW Han. Characteristics of αs2-casein Gene using PCR Technique in Korean Native Goat. Journal of Animal Science & Technology 42(4):433-442, 2000.
44. Lee S, and BC Sang. Association Traits with Bovine Leukemia Virus Resistance in Holstein and Korean Cattle. Korean Journal of Agricultural Science 27(2):101-106, 2000.
45. Sang BC, SH Ryoo and S Lee. Analysis of Sequence on Promoter of κ-casein Genes in Korean Native Cattle and Holstein. Korean Journal of Agricultural Science 27(1):33-38, 2000.
46. Lee S, CS Lee, KY Lee, TS Park, JY Han, SK Kim and BC Sang. Association of Microsatellite Polymorphisms of BoLA-DRB3 intron2 with Economic Traits in Holstein and Korean Cattle. Journal of Animal Science & Technology 42(6):757-766, 2000.
47. Lee S, KW Seo, I Kwon, CK Sung, SK Kim and BC Sang. Analysis of Genetic Polymorphisms and Similarity using Random Amplified Polymorphic DNAs in Cattle. Korean Journal of Agricultural Science 26(2):39-48, 1999.
48. Sang BC, S Lee, SH Ryoo, GW Seo, SW Han and SK Kim. Identification of Korean Native Goat Meat using DNA analysis. J. of Agri. Sci. of Chungnam Nat’l Univ 26(2):33-38, 1999.
49. Sang BC, SW Han, HD Shin, SH Ryoo and S Lee. Association between Genetic Polymorphism of Blood Protein and Meat Production Traits in Korean Native Cattle. Korean Journal of Agricultural Science 25(1):68-78, 1998.
50. Kang HB, SH Ryoo, S Lee, BS Jeon and BC Sang. Characterization of Bovine Lymphocyte Antigen DRB3 exon2 Gene of Korean Native Cattle. Korean Journal of Agricultural Science 25(1):79-88, 1998.
51. Jin HJ, HK Lee, CI Kim, DS Son, S Lee, CY Cho, KJ Han, SH Na and BH Park. The Effects of Specific Genetic Marker on the Quantitative Traits in Holstein Bulls. R.D.A. J. of Livestock Science 40(1):13, 1998.
52. Sang BC, SH Ryoo, S Lee, CE Song, MS Nam and BS Jeon. Study on the Analysis of β-lactoglobulin and κ-casein genotypes of Cattle using Polymerase Chain Reaction. Korean Journal of Agricultural Science 25(2):216-224, 1998.
53. Sang BC, SW Han, SH Ryoo, S Lee, SK Kim, HD Shin and JH Kim. Association of the Genetic Polymorphism of β-lactoglobulin and κ-casein with Preweaning Body Weights using PCR-RFLP in Korean Cattle. Animal Genetics and Breeding 2(2):125, 1998.
54. Sang BC, SH Ryoo, S Lee, SW Han and BS Jeon. Association between Genetic Polymorphisms of bloods proteins and Preweaning Body weights in Korean Native Goat. Animal Genetics and Breeding 1(4):251, 1997.
55. Sang BC, SH Ryoo, S Lee, SW Han and CS Lee. Genetic Polymorphisms of Blood Proteins and Enzymes in Korean Native Cattle. Korean Journal of Agricultural Science 22(2):170-179, 1995.

Abstracts

1. Kinsely A, Dai Y, Lee S, Wilke RN, How J, Fellman Bm Taylor Js, Ramondetta LM, Grinsfelder MO, Cobb LP, Boruta DM, Richarso G, Soliman PT, Shafer A, Westin SN, Fleming ND, Sims T, Sood AK, Ramirez PT, Lu K, and Jazaeri AA. Minimal residual disease as a prognostic marker and opportunity for intervention in advanced ovarian cancer. IGCS 2024 Annual Global Meeting, 2024.
2. Ogata J, Tarney C, Mhawech-Fauceglia P, Oliver J, Abulez T, Hood B, Conrads K, Rosalik K, Wong KK, Gershenson D, Lee S, Sood AK, Darcy K, Phippen N, Maxwell GL, Conrads T, Bateman NW. Deep Quantitative Proteomics Identifies Conserved Proteome Alterations in Low and High-Grade Serous Ovarian Cancers. American Society on Mass Spectrometry:318303, 2024.
3. Corvigno S, Asare A, Yao J, Zhao L, Fleming N, Celestino J, Hajek RA, Goette NA, Rogers RT, Nguyen TV, Montoya RN, Lu KH, Jazaeri AA, Westin SN, Sood AK, and Lee S. Identification of novel chemotherapy-related CHIP variations in patients with high-grade serous ovarian cancer. Cancer Research 84(6_Supplement), 2024.
4. Amma A, Corvigno S, Yao J, Zhao L, Fleming ND, Celestino J, Hajek RA, Kim MS, Legarreta AF, Lu KH, Takahashi K, Futreal PA,Jazaeri AA, Westin SN, Sood AK, and Lee S. Landscape of clonal hematopoiesis prior to PARP inhibitor treatment in patients with ovarian cancer. Cancer Research 84(6_Supplement), 2024.
5. Glassman D, Kim M, Spradlin M, Bada S, Bhattacharya P, Duta P, Kinsley CV, Foster KI, Bayraktar E, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin LS, Nagrath D, and Sood AK. Bridging bench to bedside: Unveiling and targeting resistance to anti-angiogenesis therapy. Felix Rutledge Society meeting, 2024.
6. Asare A, Fleming ND, Bateman N, Westin SN, Jazaeri AA, Yao J, Hajek RA, Celestino J, Fellman B, Rangel K, Sey E, Cronin SP, Phippen NT, Lu KH, Conrads, T, Maxwell GL, Lee S, AK Sood AK. Cracking the code: Understanding molecular signatures in ovarian cancer subgroups undergoing primary treatment. Gynecology Oncology(Supplement), 2024.
7. Asare A, Corvigno S, Fellman B, Fleming ND, Westin S, Lee S, Takahashi K, Sood AK. Finding the needle in the haystack: identifying risk of MDS/AML after PARP inhibitor treatment. Gynecology Oncology(Supplement), 2024.
8. Knisely A, Lee S, Wilke RN, How JA, Fellman B, Scalise CB, Dutta P, ElNaggar A, Liu M, Taylor JS, Ramondetta LM, Grinsfelder MO, Cobb LC, Boruta DM, Richardson G, Soliman PT, Shafer A, Westin SN, Fleming ND, Sims T, Sood AK, Ramirez RT, Lu KH, Jazaeri AA. Prognostic implications of detectable ovarian cancer minimal residual disease after frontline therapy by second look laparoscopy and circulating tumor DNA. Gynecology Oncology(Supplement), 2024.
9. Glassman D, Handley KF, Foster KF, Asare, A, Sims TT, Fleming ND, Lee S, Celestino J, Rangel KM, Sood AK. Does cancer appearance reflect genetic status? The relationship between the gross appearance of HGSOC and BRCA mutation status. Gynecology Oncology(Supplement), 2024.
10. Stur E, Westin SN, Fellman B, Conrads T, Abulez T, Chu Y, Bateman MW, Lee S, Yuan Y, Tran H, Conrads KA, Hood BL, Soliman PT, Fleming ND, Cobb L, Shafer A, Taylor J, Jazaeri A, Frumovitz M, Ramirez PT, Meyer LA, Alvarado T, Hull S, Lu KH, Mills GB, Wang L, Maxwell GL, Coleman RL, Sood AK. Molecular markers of response to enzalutamide-based therapy in advanced or recurrent endometrioid endometrial adenocarcinoma. Gynecology Oncology(Supplement), 2024.
11. Tarney CM, Fauceglia P, Ogata J, Oliver J, Abulez T, Hood BL, Conrads KA, Wong KK, Gershenson D, Lee S, Sood AK, Darcy KM, Phippen NT, Maxwell GL, Conrads TP, Bateman NW. Deep Quantitative Proteomics Identifies Elevated CA-125 in Low Compared to High Grade Serous Ovarian Carcinoma. Gynecology Oncology(Supplement), 2024.
12. Corvigno S, Asare A, Yao J, Zhao L, Fleming ND, Celestino J, Hajek RA, Arboleda Gotte EA, Rogers RT, Lu KH, Jazaeri AA, Westin SN, Sood AK, Lee S. Hidden Threats: Chemotherapy-related clonal Hematopoiesis in patients with ovarian cancer. Gynecology Oncology(Supplement), 2024.
13. Dai Y, Knisely A, Julio I, Lawson B, Lee S, Dai E, Faustino AL, Melendez B, Wani KM, Lu W, Shi O, Chen J, Chelvanambi M, Gibson LA, Johnson SB, Yeh CC, Ingram DR, Hudgens CW, Liu Y, Cho KS, Pei G, Jiang J, Chu Y, Liu Y, Lazar AJ, Gao J, Wargo J, Haymaker C, Soto L, Jazaeri AA, Wang L. The single-cell and spatial immune landscape of ovarian cancer. Society for Imunotherapy Cancer:847, 2024.
14. Pourebrahim R, Khanna P, Yang D, Muftuoglu M, Ostermann LB, Khazaei S, Zhao R, Asare A, Hajek RA, Lee S, Corvingo S, Gagea M, Sood A, Li R, Takahashi K, Andreeff M. Mitigating Therapy-Related Myeloid Neoplasia inp53-Mutant Clones through Targeted DNA RepairPathway Inhibition with PARP Inhibitors. American Society of Hematology:208373, 2024.
15. Asare A, Corvigno S, Fellman B, Fleming N, Jazaeri AA, Westin SN, Lee S, Takahashi K, Sood AK. Diagramming the development of MDS/AML after treatment with PARP inhibitors. Gynecology Oncology 176(Supplement 1):S309-S310, 2023.
16. Knisely A, Nitecki R, Dan M, Lee S, Fellman B, Rauh-Haina JA, Hillman RT, Taylor JS, Ramondett RM, Grinsfelder MO, Cobb LP, Boruta DM, Richardson G, Soliman PT, Shafer A, Westin SN, Fleming ND, Sood AK, PRamirez PT, Lu KH, Wang L, and Jazaeri AA. Transforming frontline therapy in ovarian cancer by focusing on surgically documented minimal residual disease after frontline treatment. Gynecology Oncology 176(Supplement 1):S122-S123, 2023.
17. Dutta P, D Glassman, MS Kim, M Spradlin, E Bayraktar, E Stur, L Mangala, K Foster, S Lee, TA Yap, SN Westin, L Eberlin, AK Sood, P Bhattacharya. Assessing Glutaminase Inhibition Treatment Response in Ovarian Cancer by Hyperpolarized Magnetic Resonance Spectroscopy. ISMRM 2023 Annual Meeting, 2023.
18. Corvigno S, Yao J, Zhao L, Asare A, Celestino J, Hajek R, Kim MS, Arboleda Goette EA, Song P, Zhang QC, Song X, Mohammad MM, Shaw KR, Zhang J, Lu KH, Jazaeri AA, Westin SN, Sood AK, and Lee S. Genomic profiling of chemotherapy-related clonal hematopoiesis in patients with high-grade serous ovarian cancer. Cancer Research 83(7_Supplement), 2023. e-Pub 2023.
19. Stur E, Peng F, Teng B, Bayraktar E, Hu M, Corvigno S, Brown DJ, Lee S, Moore KN, Maxwell GL, Conrads TP, Fleming N, Navin N, Wang L, Sood AK. The dynamic immune behavior of primary and metastatic tumors of ovarian cancer. Cancer Research 83(7_Supplement), 2023.
20. Kim MS, Glassman D, Lankenau Ahumada A, Bayraktar E, Jennings NB, Joseph R, Lee S, Coleman R, Sood AK. Mechanisms of and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Research 83(7_Supplement), 2023.
21. Asare A, Glassman D, Ajami NJ, Wong M, Foster K, Corvigno S, Afshar-Kharghan V, Fleming N, Lee S, Wargo J, and Sood AK. Partners in crime: the relationship between the ovarian tumor microbiome and venous thromboembolism. Gynocology Oncology 176(Supplement):S293-S294, 2023.
22. Laberiano-Fernandez C, Arrechedera C, Tamegnon A, Hajek RA, Celestino J, Wistuba J, Lee S, Jazaeri AA, Parra ER. Classification of the Tumor Microenvironment in the Ovarian Cancer Patient’s Tissues Could Drive a New Therapeutically Approach. USCAP 2023 Annual Meeting:160, 2023.
23. Foster KI, J Yao, L Zhao, A Asare, S Corvigno, S Lee, SN Westin, GL Maxwell, NW Bateman, TR Conrads, and AK Sood. Spatial Heterogeneity of Homologous Recombination Deficiency Status in High-Grade Serous Ovarian Cancer. Gynecology Oncology 117(Supplement), 2023.
24. Hinchcliff EM, Patel A, Fellman BM, Yuan Y, Chelvanambi M, Wargo J, Liu YY, Liu J, Lee S, Roszik J, Hillman RT, Westin SN, Sood AK, Soliman PT, Frumovitz MM, Shafer A, Meyer LA, Fleming ND, Gershenson DM, Vining DJ, Ganeshan D, Vining, Ganeshan D, Lu KH, Jazaeri AA. Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors. Gynecology Oncology 166(Supplement 1):S66, 2022.
25. Foster KI, Shaw KR, Jin J, Westin SN, Yap TA, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Fleming ND, Sood AK. The devil you know: A population-level analysis of tumor-based next-generation sequencing of high-grade epithelial ovarian cancer. Gynecology Oncology 166(Supplement 1):S91-S92, 2022.
26. Glassman D, Kim M, Badal S, Spradlin M, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, Wuchu F, Bayraktar E, Wu Y, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin L, Nagrath D, Sood AK. What’s next after bevacizumab resistance? Targeting metabolic vulnerabilities in ovarian cancer. Gynecology Oncology 166(Supplement 1):S17-S18, 2022.
27. Glassman D, Bateman NW, Conrads TP, Lee S, Zhao L, Ivan C, Rangel K, Zhang J, Futreal PA, Fleming ND, Afshar-Kharghan V, Maxwell GL, Yao J, Tan Y, Chen K, Sood AK. Why are thromboembolic events so common in ovarian cancer? An investigation of tumor-mediated molecular markers. Gynecology Oncology 166(Supplement 1):S129-S130, 2022.
28. Glassman D, Kim MS, Dutta P, Kingsley C, Bayraktar E, Wu Y, Stur E, Mangala L, Foster K, Lee S, Yap TA, Westin SN, Bhattacharya PK, Sood AK. Hyperpolarized magnetic resonance spectroscopy assessment of the metabolic effects of glutaminase inhibitor therapy in an ovarian cancer model. Cancer Research 82(12_Suppl):2484, 2022.
29. Foster KI, Shaw KR, Jin J, Westin SN, Yap TA, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Fleming ND, Sood AK. Clinical implications of tumor-based next-generation sequencing in ovarian cancer. 2022 ASCO Annual Meeting:5545, 2022. e-Pub 2022.
30. Lee S, Zhao L, Fleming ND, Celestino J, Hajek RA, Morgan MB, Liu Y, Westin SN, Jazaeri AA, Liu J, Zhang J, Futreal PA, Sood AK. Transcriptomic profiles of response to neoadjuvant chemotherapy in patients with high-grade serous ovarian cancer. Cancer Research 82(12_Suppl), 2022.
31. Zhao L, Ma S, Fleming ND, Celestino J, Kim MS, Hajek RA, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee S. Distinct molecular profiles of serum-derived extracellular vesicles in high-grade serous ovarian cancer. Cancer Research 82(12_Suppl), 2022.
32. Corvigno S, Keating M, Spraldin ML, Badal S, Silva ID, Elaine Stur, Darcy KM, Liu J, Fleming ND, Lee S, Eberlin LS, Sood AK. Metabolic profiling of pre- and post-treatment ovarian cancer tissues using in situ analyses. Cancer Research 82(12_Suppl), 2022.
33. Stur E, Corvigno S, Xu M, Chen K, Lee S, Liu J, Ricco E, Fleming ND, Kraushaar D, Zhang J, Sood AK. Spatially resolved transcriptomics to understand mechanisms of response to neoadjuvant chemotherapy. Cancer Research 82(12_Suppl), 2022.
34. Nitecki R, Dang M, Lee S, Fellman B, Rauh-hain A. Hillman T, Taylor JS, Ramondetta LM, Grinsfelder MO, Cobb LP, Boruta DM, Richardson G, Pamela T. Soliman, Aaron Shafer, Westin SN, Fleming ND, Sood AK, Tanguma C, Ramirez PT, Lu KH, Wang L, Jazaeri AA. Initial clinicopathologic and molecular characterization of minimal residual disease detected by second look laparoscopy after completion of frontline surgery and chemotherapy in patients with advanced stage ovarian cancer. Cancer Research 82(12_Suppl), 2022.
35. Pereira I, S Badal, S Corvingo, J Lin, S Lee, J Liu, AK Sood, and LS Eberlin. Desorption electrospray ionization mass spectrometry imaging to predict and understand response to neoadjuvant chemotherapy treatment of ovarian cancer. American Society on Mass Spectrometry (65th ASMS):308491, 2021.
36. Lee S, L Zhao, LD Little, SN Westin, AA Jazaeri, ND Fleming, J Zhang, PA Futreal, AK Sood. Distinct T cell receptor diversity and integrative analyses of clinically defined high-grade serous ovarian cancer. Gynecology Oncology 162(Supplement):S138, 2021.
37. Glassman D, S Lee, L Zhao, C Ivan, K Rangel, J Zhang, PA Futreal, N Fleming, V Afshar-Kharghan, AK Sood. Messages from the genome: The genetic makeup of ovarian cancer and risks of venous thromboembolism. Gynecology Oncology 162(Supplement):S205-S206, 2021.
38. Handley KF, TT Sims, D Glassman, ND Fleming, S Lee, H Yao, J Yao, J Liu, RC Bast, SN Westin, J Celestino, KM Rangel, TP Conrads, GL Maxwell, PT Ram, AK Sood. If Looks Could Kill: Morphologic Subtypes of High-Grade Serous Ovarian Cancer. Gynecology Oncology 162(Supplement):S20-S21, 2021.
39. Lee S, L Zhao, J Celestino, RA Hajek, MB Morgan, MS Kim, SN Westin, AA Jazaeri, ND Fleming, J Liu, J Zhang, PA Futreal, AK Sood. NF1 copy number alterations in clinically-defined subsets of high-grade serous ovarian cancers. Cancer Research 81(13 Supplment), 2021.
40. Kim MS, K Noh, DH Bach, HJ Choi, SY Wu, S Pradeep, I Cristina, MS Cho, E Bayraktar, C Rodriguez-Aguayo, SK Dasari, E Stur, S Lee, LS Mangala, G Lopez-Berestein, AK Sood. The Hidden role of Paxillin: Localization to Nucleus Promotes Tumor Angiogenesis. AACR Annual Meeting 2021 81(13_Supplement), 2021.
41. Lee S, L Zhao, C. Rojas, N.W. Bateman, H. Yao, O.D. Lara, A.A. Jazaeri, J. Liu, J.K. Burks, N.D. Fleming, K.H. Lu, S.N. Westin, R.L. Coleman, G.B. Mills, J. Zhang, T.P. Conrads, G.L. Maxwell, P.A. Futreal and A.K. Sood. A high-depth multi-omics analysis of clinically defined subsets of high-grade serous ovarian cancer. Gynecology Oncology 159(Supplement 1):87, 2020.
42. Rojas C, Bateman NW, S Lee, N Fleming, CC Hamilton, K Conrads, K Wilson, J Loffredo, B Hood, M Zhou, KM Darcy, Y Casablanca, TP Conrads, AK Sood, and L Maxwell. Excellent versus poor response to neoadjuvant chemotherapy is accompanied by unique proteome alterations in post versus pre-treatment HGSOC tumors. Society of Gynecologic Oncology 159(Supplement 1), 2020.
43. Lee S, L Zhao, SN Westin, NW Bateman, AA Jazaeri, ND Fleming, KH Lu, RL Coleman, GB Mills, J Zhang, TP Conrads, GL Maxwell, PA Futreal, and AK Sood. High-depth whole genome sequencing of clinically-annotated high-grade serous ovarian cancers. Cancer Research 80(16_Supplement):2510, 2020. e-Pub 2020.
44. Lee S, L Zhao, J Celestino, KM Rangel, RA Hajek, MS Kim, SE Sharafi, J Liu, ND Fleming, KH Lu, J Zhang, PA Futreal, GB Mills, SN Westin, AK Sood, AA Jazaeri, RL Coleman. Functional proteomic aberrations post-chemotherapy with paclitaxel and carboplatin in patients with advanced ovarian cancer. Cancer Research 80(16_Supplement):2941, 2020.
45. Westin SN, S Lee, L Zhao, Y Ying, J Wu, R Hajek, S Sharafi, L Meyer, ND Fleming, A Jazaeri, RL Coleman, KH Lu, GB Mills, J Zhang3, PA Futreal, AK. Sood. Pharmacodynamic changes by durvalumab in combination with chemotherapy in women with untreated, advanced stage ovarian cancer. Cancer Research 80(16_Supplement):CT188, 2020.
46. Badal SP, M Sans, S Lee, S Corvigno, J Lin, M Keating, J Liu, AK Sood, and L Eberlin. Identification of Metabolic Markers of Treatment Response and Adaptive Metabolic Changes in Ovarian Cancer Tissues using Mass Spectrometry Imaging. American Society for Mass Spectrometry:303909, 2020.
47. Kendsersky ND, H Ma, Y Fang, LG Campell, J Eng, S Lee, K Chin, SN Westin, and GB Mills. Single-cell proteomic analysis of the tumoral heterogeneity in response to PARP inhibitor. Clinical Cancer Research 26(13):PR03, 2019.
48. Labrie M, Ju Z, Litton JK, Kim TB, Lee S, Chen K, Soliman PT, Frumovitz M, Meyer LA, Moulder S, Jazaeri AA, Lu KH, Sood AK, Coleman RL, Mills GB, and Westin SN. Exploration of markers of synergistic lethality of PARP and PI3K-akt-mTOR inhibitors in women’s cancers. Gynecology Oncology 154(Supplement 1):1212, 2019.
49. Labrie M, Z Ju, JK Litton, TB Kim, S Lee, K Chen, PT Soliman, M Frumovitz, LA Meyer, S Moulder, AA Jazaeri, KH Lu, AK Sood, RL Coleman, GB Mills, SN Westin. Exploration of markers of synergistic lethality of PARP and PI3K-Akt-mTOR inhibitors in women's cancers. Cancer Research 79(13_Supplement):2070/7, 2019.
50. Kim MS, S Ma, C Leuschner, S Lee, RL Coleman, AK Sood. Targeting LHRH-R to improve immune response in ovarian cancer. Cancer Research 79(13_Supplement):3199/9, 2019.
51. Labrie M, Kim TB, Ju Z, Lee S, Lu Y, K Chen, GB Mills, and SN Westin. Window of opportunity trial: Assessing the adaptive response of HGSOC to PARPi for Informed combination therapies. Clinical Cancer Research 22(25_Supplement):NT-098, 2019.
52. Labrie M, Y Fang, Z Ju, JK Litton, TB Kim, K Salevieva, S Lee, CP Vellano, Y Lu, K Chen, J Celestino, J Liu, PT Soliman, MM Frumovitz, LA Meyer, S Moulder, AA Jazaeri, KH Lu, AK Sood, RL Coleman, GB Mills, SN Westin. Exploration of markers of synergistic lethality of PARP and PI3K-Akt-mTOR inhibitors in women's cancers. MDACC Moonshot SAB meeting:12A, 2019.
53. Lopes IA, M Kardosova, TM Bianco, AQ Arantes, CA Silva, PS Scheucher, DG Tenen, S Lee, EM Rego, RS Welner, M Alberich-Jorda, LL Figueiredo-Pontes. C/Ebpg (CCAAT/Enhancer Binding Protein Gamma) Balances Cytotoxic and Secretory Potential of Natural Killer Cells. Blood 132(Supplement):3721, 2018.
54. Shah T, Y Chu, S Lee, C Yin, M Barth, RR Miles, J Ayello, E Morris, L Harrison, C van de Ven, SC Goldman, MS Lim, M Hermiston, SL Perkins, and MS Cairo. Ibrutinib Significantly Enhances Programmed Cell Death and Overall Survival in Burkitt Lymphoma (BL) in NSG Xenografts: a pre-clinical study. Pediatric Blood & Cancer:P310, 2017.
55. Lee S, C Yin, J Ayello, C van de Ven, and MS Cairo. Ruxolitinib, a Jak1/Jak2 inhibitor, significantly prolongs survival in both primary mediastinal B-cell lymphoma and Hodgkin lymphoma xenograft NSG mouse model: a potential targeted adjuvant therapy. Pediatric Blood and Cancer 63(S2):S1-S65, 2016.
56. Lee S, C Yin, T Shah, J Ayello, E Morris, C van de Ven, and MS Cairo. Upregulation of DLEU1 significantly prolongs survival in a rituximab-treated DLEU1 knockout human Burkitt lymphoma (BL) xenograft NSG mouse model: DLEU1 may act as a tumor suppressor gene in pediatric BL. Cancer Research 76(Supplement):3838, 2016.
57. Lee S, C Yin, J Ayello, E Morris, C van de Ven, and MS Cairo. Downregulation of DLEU1 Significantly Shortened Survival in a Rituximab-Treated DLEU1 Knockout Human Burkitt lymphoma (BL) Xenograft NSG Mouse Model: DLEU1 May Act as a Tumor Suppressor Gene in Pediatric BL. Blood 126(33):3656, 2015.
58. Lee S, C Yin, J Ayello, E Morris, T O’Connell, L Harrison, C van de Ven, M Barth, R Miles, P Galardy, SC Goldman, M Lim, M Hermiston, L McAllister-Lucas, L Giulino-Roth, SL Perkins, and MS Cairo. Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May Be a Potential Adjuvant Agent in the Treatment of BL. Blood 126(23):5117, 2015.
59. Lee S, C Yin, J Ayello, E Morris, L Harrison, C van de Ven, M Barth, R Miles, P Galardy, SC Goldman, M Lim, M Hermiston, L McAllister-Lucas, L Giulino-Roth, SL Perkins, and MS Cairo. Ibrutinib alone and in combination with dexamethasone and carfilzomib significantly inhibits cell proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib may be a future targeted agent in combination therapy in patients with PMBL. Blood 126(23):4852, 2015.
60. Lee S, C Yin, J Ayello, E Morris, C van de Ven, and MS Cairo. Ruxolitinib Significantly Prolongs Survival in Both a Primary Mediastinal B-cell lymphoma (PMBL) and Hodgkin Lymphoma (HL) Xenograft NSG Mouse Model: Ruxolitinib May Be a Potential Adjuvant Agent in the Treatment of PMBL and of HL. Blood 126(23):2732, 2015.
61. Yin C, J Ayello, C van de Ven, MS Cairo and S Lee. Overexpression of DLEU1 gene significantly induces programmed cell death in Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 may be a tumor suppressor gene in PMBL. British Journal of Haematology 171(Supplement):87, 2015.
62. Lee S, C Yin, J Ayello, C van de Ven, C Klein and MS Cairo. Obinutuzumab (GA101) significantly inhibits cell proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab may be a future targeted agent in the treatment of PMBL. British Journal of Haematology 171(Supplement):141, 2015. e-Pub 2015.
63. Lee S, C Yin, J Ayello, C van de Ven, and MS Cairo. Ruxolitinib significantly prolonged survival in both a Primary Mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL) xenograft NSG mouse model: Ruxolitinib may be a potential adjuvant agent in the treatment of PMBL and HL. British Journal of Haematology 171(Supplement):174, 2015.
64. Lee S, C Yin, J Ayello, E Morris, C van de Ven, and MS Cairo. Regulation of DLEU1 expression significantly alters survival in rituximab-treated DLEU1 knockout and overexpressed human /Burkitt lymphoma (BL) xenograft NSG mouse model: DLEU1 may act as a tumor suppressor gene in BL. British Journal of Haematology 171(Supplement):48, 2015.
65. Lee S, C Yin, J Ayello, E Morris, C van de Ven, and MS Cairo. DLEU1 significantly alters programmed cell death in chemoimmunotherapy treated TALENs-induced DLEU1 Burkitt lymphoma (BL) knockout: DLEU1 may act as a tumor suppressor gene in BL. British Journal of Haematology 171(Supplement):151, 2015.
66. Lee S, C Yin, T O’Connell, M Barth, R Miles, J Ayello, L Harrison, C van de Ven, P Galardy, M Lim, M Hermiston, L McAllister-Lucas, LG Roth, SL Perkins, and MS Cairo. Ibrutinib significantly improves survival in a human Burkitt lymphoma (BL) xenograft NSG mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL. British Journal of Haematology 171(Supplement):152, 2015.
67. Lee S, C Yin, J Ayello, L Harrison, E Morris, C van de Ven, M Barth, R Miles, P Galardy, M Lim, M Hermiston, L McAllister-Lucas, LG Roth, SL Perkins, and MS Cairo. Ibrutinib alone and in combination with dexamethasone significantly inhibits cell proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib may be a potential targeted agent in combination therapy in patients with PMBL. British Journal of Haematology 171(Supplement):142, 2015.
68. O’Connell T, C Yin, L Harrison, J Ayello, C van de Ven, S Lee*, and MS Cairo*. Prolonged ibrutinib treatment of Burkitt lymphoma cells leads to ibrutinib resistance via changes in BTK and PLCgamma2 signaling. British Journal of Haematology 171(Supplement):172, 2015.
69. Lee S, C Yin, T O’Connell, M Barth, R Miles, J Ayello, L Harrison, C van de Ven, P Galardy, M Lim, M Hermiston, L McAllister-Lucas, LG Roth, SL Perkins, and MS Cairo. Ibrutinib, a selective and covalent inhibitor of Bruton’s tyrosine kinase, significantly inhibits Ibrutinib significantly improves survival in a human Burkitt lymphoma (BL) xenograft NSG mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL. Cancer Research 75(Supplement):2608, 2015.
70. Lee S, C Yin, T O’Connell, J Ayello, C van de Ven, and MS Cairo. DLEU1 significantly alters programmed cell death in chemoimmunotherapy treated TALENs-induced DLEU1 knockout and DLEU1 overexpressing Burkitt Lymphoma (BL): DLEU1 may act as a tumor suppressor gene in pediatric BL. Cancer Research 75(Supplement):2077, 2015.
71. O’Connell T, C Yin, L Harrison, J Ayello, C van de Ven, S Lee*, and MS Cairo*. Prolonged treatment of Burkitt lymphoma cells with ibrutinib leads to ibrutinib resistance via changes in BTK and PLCgamma2 signaling. Paul Woolf Pediatric Research Conference, 2015.
72. O’Connell T, C Yin, L Harrison, J Ayello, C van de Ven, S Lee* and MS Cairo*. . Prolonged treatment of Burkitt lymphoma cells with ibrutinib lead to ibrutinib resistance via changes in the apoptotic mechanism. Graduate Student Research Forum, New York Medical College, Valhalla, NY, 2015.
73. Yin C*, S Lee*, T O’Connell, J Ayello, C van de Ven, and MS Cairo. Obinutuzumab (GA101) significantly inhibits cell proliferation and induces programmed cell death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab may be a future targeted agent for the treatment of PMBL. Blood 124(21):4492, 2014.
74. O’Connell T, C Yin, J Ayello, C van de Ven, S Lee*, and MS Cairo*. Obinutuzumab, a novel, anti-CD20 targeted monoclonal antibody, induces significant anti-proliferative and apoptotic effects, and significantly modifies cell signaling pathways in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab may be a future potential targeted agent for treatment of PMBL. The 4th Paul Woolf Research Conference, 2014.
75. Yin C, O’Connell T, M Barth, R Miles, J Ayello, L Harrison, C van de Ven, P Galardy, M Lim, M Hermiston, L McAllister-Lucas, LG Roth, S Perkins, S Lee* and MS Cairo*. Ibrutinib, a selective and covalent inhibitor of Bruton’s tyrosine kinase, significantly inhibits cell proliferation and induces apoptosis in Primary Mediastinal B-Cell lymphoma (PMBL): Ibrutinib may be a future targeted agent in combination therapy in patients with PMBL. ASH meeting on Lymphoma Biology:66734, 2014.
76. O’Connell T, C Yin, M Barth, R Miles, J Ayello, L Harrison, C van de Ven, P Galardy, M Lim, M Hermiston, L McAllister-Lucas, LG Roth, S Perkins, S Lee*, and MS Cairo*. Ibrutinib significantly alters cell proliferation and programmed cell death in Burkitt lymphoma (BL): Ibrutinib may be a potential adjuvant agent in the treatment of BL. ASH meeting on Lymphoma Biology, 2014.
77. Lee S, C Yin, T O’Connell, J Ayello, C van de Ven, and MS Cairo. Down-regulation of DLEU1 Significantly Inhibits Programmed Cell Death in Rituximab and Cyclophosphamide Treated TALENs-Mediated DLEU1 Knockout Burkitt Lymphoma (BL): DLEU1 may act as a tumor suppressor gene in pediatric BL. ASH meeting on Lymphoma Biology:66633, 2014.
78. O’Connell T, C Yin, M Barth, R Miles, J Ayello, L Harrison, C van de Ven, P Galardy, M Lim, M Hermiston, L McAllister-Lucas, LG Roth, S Perkins, S Lee*, and MS Cairo*. Ibrutinib significantly alters cell proliferation and apoptosis in BL and PMBL: Ibrutinib may be a potential adjuvant therapy in the treatment of BL and/or PMBL. Pediatric Blood and Cancer 61(S2):139, 2014.
79. O’Connell T, C Yin, J Ayello, C van de Ven, S Lee* and MS Cairo*. Ibrutinib (PCI-32765), a selective and covalent inhibitor of burton’s tyrosine kinase, significantly inhibits cell proliferation and enhance programmed cell death in Burkitt lymphoma (BL): Ibrutinib may be a potential therapeutic agent for treatment of BL. Graduate Student Research Forum. NYMC, 2014.
80. Lee S, C Yin, T O’Connell, J Ayello, C van de Ven, and MS Cairo. Transcription Activator-Like Effector Nucleases (TALENs) mediated silencing of Bruton’s tyrosine Kinase (BTK) inhibits phosphorylation of Erk in Burkitt lymphoma. Cancer Research 74(19 Suppl):3112, 2014.
81. Lee S, C Yin, J Ayello, C van de Ven, and MS Cairo. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (CAS) system mediated endogenous CD19 gene knockout model in Burkitt Lymphoma. Cancer Research 74(Supplement):3617, 2014.
82. Yin C, T O’Connell, J Ayello, C van de Ven, S Lee* and MS Cairo*. Obinutuzumab (GA101) significantly induces anti-proliferative effects and programmed cell death, and significantly down-regulates cell signaling pathways in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab may be a future potential targeted agent for treatment of PMBL. Cancer Research 74(Supplement):3096, 2014.
83. O’Connell T, C Yin, J Ayello, C van de Ven, S Lee*, and MS Cairo*. DLEU1 knockout by Transcription Activator-Like Effector Nuclease (TALENs) inhibits Apoptosis in Pediatric Burkitt Lymphoma (PBL): DLEU1 may serve as a tumor suppressor gene (or mechanism) in PBL. The Eastern Society for Pediatric Research (SPR) Annual Meeting, 2013.
84. O’Connell T, C Yin, J Ayello, C van de Ven, S Lee*, and MS Cairo*. DLEU1 knockout by Transcription Activator-Like Effector Nuclease (TALENs) inhibits Apoptosis in Pediatric Burkitt Lymphoma (PBL): DLEU1 may serve as a tumor suppressor gene (or mechanism) in PBL. The Pediatric Academic Societies (PAS) Annual meeting, 2013.
85. Lee S, C Yin, T O’Connell, J Ayello, C van de Ven, and MS Cairo. Sequence-specific TALENS-induced DLEU1 Gene Disruption Significantly Suppresses Apoptosis and Increases phosphorylation of AKT and IkBa in Pediatric Burkitt Lymphoma (PBL): DLEU1 may act as a Tumor Suppressor Gene in PBL. Blood 122(21):1279, 2013.
86. Lee S, C Yin, J Ayello, T O’Connell, C van de Ven, M Muniz, MJ Barth, and MS Cairo. Exogenous Overexpression of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation in Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells to RTX Induced Apoptosis. Blood 122(21):2503, 2013.
87. Lee S, C Yin, J Ayello, M Genualdi, C van de Ven, and MS Cairo. Transcription Activator like Effector Nucleases (TALENs) Mediated CD20 Gene Knockout Burkitt Lymphoma Model. Blood 122(21):4883, 2013.
88. Yin C, T O’Connell, J Ayello, C van de Ven, S Lee*, and MS Cairo*. Obinutuzumab (GA101), a novel type II glycoengineered CD20 antibody, significantly induced programmed cell death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab may be a future potential targeted agent for the treatment of PMBL. Blood 122(21):5146, 2013.
89. Yin C, TH Chung, J Ayello, TH Park, C van de Ven, and MS Cairo, and S Lee. Overexpression of Deleted in Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 may be a tumor suppressor gene in a subset of patients with PMBL. Blood 122(21):3852, 2013.
90. Pais F, S Lee, V Rodic, MJ Barth, MS Cairo, M Hermiston, and RR Miles. Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion of MIR17HG in Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity. Blood 122(21):243, 2013.
91. O’Connell T, C Yin, J Ayello, C van de Ven, S Lee*, and MS Cairo*. DLEU1 Knockout by Transcription Activator-Like Effector Nucleases (TALENs) Inhibits Programmed Cell Death in Pediatric Burkitt Lymphoma (PBL) Indicating Its Role as a Potential Tumor Suppressor Gene. 50th GSBMS. New York Medical College, 2013.
92. Lee S, C Yin, T O’Connell, J Ayello, C van de Ven, and MS Cairo. Sequence-specific TALENS-induced endogenous DLEU1 knockout significantly inhibits chemotherapy-induced programmed cell death in Pediatric Burkitt Lymphoma (PBL): DLEU1 may act as a Tumor Suppressor Gene in PBL. The 3rd Pediatric Research symposium, 2013.
93. Lee S, C Yin, J Ayello, C van de Ven, and MS Cairo. Transcription activator-like effector nucleases (TALENS) mediated DLEU1 Gene disruption suppresses apoptosis in Pediatric Burkitt Lymphoma (PBL): DLEU1 maybe a tumor suppressor gene in PBL. Pediatric Blood and Cancer 60(S3):S264, 2013.
94. Yin C, S Lee, J Ayello, C van de Ven, and MS Cairo. Ruxolitinib, a JAK1/JAK2 inhibitor, inhibits cell proliferation and induces apoptosis in Hodgkin Lymphoma (HL) and Primary Mediastinal B-cell Lymphoma (PMBL). Pediatric Blood and Cancer 60(S3):264, 2013.
95. O’Connell T, C Yin, J Ayello, C van de Ven, S Lee*, and MS Cairo*. Transcription activator-like effector nucleases (TALENs) induced DLEU1 gene knockout inhibitor programmed cell death in pediatric Burkitt Lymphoma (PBL): DLEU1 maybe a tumor suppressor gene in PBL. The 3rd Paul Woolf Research conference, 2013.
96. O’Connell T, C Yin, J Ayello, C van de Ven, S Lee*, and MS Cairo*. Obinutuzumab, a novel type II glycoengineered CD20 antibody induced programmed cell death in Primary Mediastinal B-cell Lymphoma (PMBL) cell: Obinutuzumab may be a future potential targeted agent for the treatment of PMBL. The 3rd Paul Woolf Research conference, 2013.
97. Yong KJ, C Gao, J Lim, B Yan, H Yang, T Dimitrov, A Kawasaki, CW Ong, S Lee, S Ravikumar, S Sivastava, X Tian, JM Luk, YY Dan, M Salto-Tellez, L Chai, and DG Tenen. Stem cell factor SALL4 as a prognostic marker and therapeutic target for the aggressive progenitor-like subgroup of hepatocellular carcinoma. APASL Liver Week. Singapore, 2013.
98. Madris BD, C Yin, J Ayello, C van de Ven, S Lee* and MS Cairo*. Transcription activator-like effector nucleases mediated DLEU1 gene knockdown suppresses apoptosis in Burkitt’s lymphoma. The Eastern Society for Pediatric Research (SPR) Annual Meeting, 2013.
99. Madris BD, C Yin, J Ayello, C van de Ven, S Lee* and MS Cairo*. Transcription activator-like effector nucleases mediated DLEU1 gene knockdown suppresses apoptosis in Burkitt’s lymphoma. The Pediatric Academic Societies Annual meeting, 2013.
100. Lee S, C Yin, J Ayello, C van de Ven, HT Kwang, CP Biggar, J Pao, E Mulvey and MS Cairo. TALENS-Mediated DLEU1 Gene Silencing in Burkitt Lymphoma (BL): Implication of lncRNA DLEU1 Gene as a Potential Tumor Suppressor Gene in BL. Blood 120(21):2403, 2012.
101. Lee S, C Yin, J Ayello, C van de Ven, CP Biggar, HT Kwang, E Mulvey, J Pao and MS Cairo. Overexpression of Deleted Lymphocytic Leukemia 1 (DLEU1) Inhibits Proliferation of Burkitt Lymphoma (BL). Blood 120(21):2654, 2012.
102. Yin C, S Lee, J Ayello, C van de Ven, J Pao, E Mulvey and MS Cairo. JAK1/JAK2 inhibitor, Ruxolitinib Inhibits Cell Proliferation and Induces Apoptosis in Hodgkin Lymphomas (HL) and Primary Mediastinal B-cell Lymphomas (PMBL). Blood 120(21):4886, 2012.
103. Lee S, C Yin, J Ayello, C van de Ven, BD Madris, HT Kwang, CP Biggar, J Pao, E Mulvey, and MS Cairo. Transcription activator-like effector nucleases Mediated DLEU1 Gene Knock down in Raji Burkitt Lymphoma cells: Implication of a Potential Tumor Suppressor Gene in Burkitt Lymphoma. 2nd Annual Assistant Professor PRS, 2012.
104. Lee S, C Yin, J Ayello, C van de Ven, HT Kwang, CP Biggar and MS Cairo. DLEU1 TALENS-Mediated Loss of Function in Burkitt Lymphoma (BL) Raji Cells: Implication of lncRNA DLEU1 Gene as a Tumor Suppressor Gene. British Journal of Haematology 159(S1):54, 2012.
105. Lee S, C Yin, J Ayello, C van de Ven, HT Kwang, CP Biggar and MS Cairo. Silencing of Long Non-Coding RNA DLEU1 Gene by Transcription Activator-like Effector Nucleases (TALENS) in Burkitt Lymphoma Cells. British Journal of Haematology 159(S1):54, 2012.
106. Yin C, S Lee, J Ayello, C van de Ven and MS Cairo. Inhibitory effect of Ruxolitinib (JAK2 inhibitor) on JAK2 signaling, proliferation and induction of apoptosis Hodgkin (HL) and primary mediastinal B-cell (PMBL) adolescent and young adult (ANA) lymphomas. British Journal of Haematology 159(S1):54, 2012.
107. Yong KJ, C Gao, J Lim, B Yan, H Yang, T Dimitrov, A Kawasaki, CW Ong, S Lee, S Srivastava, X Tian, JM Luk, YY Dan, M Salto-Tellez, L Chai and DG Tenen. Stem Cell Factor Sall4 As A Prognostic Marker And Therapeutic Target For Advanced Hepatocellular Carcinoma. The Sixth Annual International Liver Cancer Association, 2012.
108. Lee S, NS Day, J Ayello, C van de Ven, A Harrison, M Muniz, and MS Cairo. Long non-coding RNA DLEU1 gene knockdown with cyclophosphamide and/or rituximab induced apoptosis in pediatric Burkitt lymphoma (BL); Implication DLEU1 as a tumor suppressor gene. 1st Annual Assistant Professor Research Symposium, 2012.
109. Yong KJ, A Kawasaki, S Lee, B Yan, H Yang, CW Ong, S Srivastava, T Dimitrov, C Gao, JM Luk, YY Dan, M Salto-Tellez, L Chai and DG Tenen. Re-activation of the stem cell factor SALL4 and its role in hepatocellular carcinoma. The 10th global COE international symposium:P-27, 2011.
110. Yong KJ, A Kawasaki, S Lee, B Yan, H Yang, CW Ong, S Srivastava, T Dimitrov, C Gao, JM Luk, YY Dan, M Salto-Tellez, L Chai and DG Tenen. Re-activation of the stem cell factor SALL4 and its role in hepatocellular carcinoma. Frontier Cancer Science of Singapore, 2011.
111. Ravikumar S, Yada S, Lai YS, Tenen DG and S Lee. Regulation of human Sall4 gene in normal and cancer states. Frontiers in Cancer Science of Singapore:P20, 2010.
112. Ebralidze AK, A Di Ruscio, S Lee, KB O’Brien and DG Tenen. Epigenetic Control of C/EBPa by Distant Synergic Regulatory Elements. Blood 114(22):1470, 2009.
113. Lee S, AK Ebralidze AK, A Di Ruscio, LM Liew, KB O’Brien, S Koschmieder and DG Tenen. Characterization of the Distal Elements mediating transcriptional regulation of C/EBPa. Frontiers in Cancer Science of Singapore:P27, 2009.
114. Zhou YD, S Lee, Z Jin, M Wright and MP Anderson. Arrested developmental down-regulation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy. The 38th annual meeting of the Society for Neuroscience, 2008.
115. Anderson MP, YD Zhou and S Lee. Temporal lobe epilepsy-related protein Lgi1 regulates hippocampal perforant pathway glutamatergic synaptic transmission. The 61st annual meeting of American Epilepsy society, 2007.
116. Zhou YD, S Lee and MP Anderson. Temporal lobe epilepsy-related protein Lgi1 regulates hipppocampal perforant pathway synaptic transmission by reducing the probability of transmitter release. The 37th annual meeting of the Society for Neuroscience, 2007.
117. Anderson MP, YD Zhou and S Lee. Effects of the human autosomal dominant lateral temporal lobe epilepsy gene LGI1 on the hippocampal dentate gyrus. Curing Epilepsy, 2007.
118. Kasten M, S Lee, Anderson MP. Auditory thalamus hyperexcitability in a mouse model of human autosomal dominant lateral temporal lobe epilepsy. Epilepsia 47:280, 2006.
119. Atefy R, S Lee, T Mochizuki, TE Scammell, DL Schomer and MP Anderson. Chronic EEG Recordings in a Mouse Model of Human Autosomal Dominant Lateral Temporal Lobe Epilepsy. 60th Annual Meeting of the American Epilepsy Society, 2006.
120. Lee S and Anderson MP. Defining the protein complex associated with T-type Ca2+ channel Cav3.1 using epitope-tagged CACNA1G transgenic mice. The 35th society for neuroscience annual meeting, 2005.
121. Lee S, C Andrieu, V Pouchkine, J Auclair, B Salaun, E Cahir-McFarland, R Kobayashi, G Mosialos, E Kieff and BS Sylla. The RasGAP-associated Protein p62dok1 (Dok1) Is a Substrate for IKKβ. Keystone Meeting, 2002.
122. Sang BC, SH Ryoo and S Lee. Molecular genetic characteristic of the k-casein and beta lactoglobulin genes in Korea cattle. Proceedings of the 9th Annual Congress of the Asian-Australasian Association of Animal Production Societies, 2000.
123. Sang BC, S Lee, JA Kim and SW Han. . The Genetic Characteristics of β-casein Gene using PCR-RFLP in Korean Native Goat. Proceedings of the 9th Annual Congress of Animal Sciences and Technology:PA20069, 2000.
124. Lee S and BC Sang. Association of Microsatellite Polymorphisms of BoLA-DRB3 intron2 with Economic Traits in Holstein and Korean Cattle. Proceedings of the 9th Annual Congress of Animal Sciences and Technology, 2000.
125. Lee S, BC Sang, SK Kim and YJ Park. The Genetic Polymorphisms of the BoLA-DYA Gene in Cattle. Proceedings of the 9th Annual Congress of Animal Sciences and Technology, 2000.
126. Lee S, BC Sang, SK Kim and YJ Park. The Association of Genetic Polymorphisms of the BoLA-DRB3 Gene with Economic Traits in Cattle. Proceedings of the 9th Annual Congress of Animal Sciences and Technology:PA20066, 2000.
127. Kim HB, HS Kim, S Lee, TH Kim, YH Hong, NH Park and JI Jung. The Study on the Relation Test between Economic Traits and Microsatellite locus by Comparative linkage map. Proceedings of the 8th Annual Congress of Animal Sciences and Technology, 1999.
128. Kim HS, CD Kim, S Lee, HB Kim, EW Park, BD Sang and IC Cheong. A polymorphism study of chicken prolactin and prolactin-receptor gene related to broodiness. Proceedings of the 8th Annual Congress of Animal Sciences and Technology, 1999.
129. Ryoo SH, BC Sang, SR Ryoo, TH Lee, S Lee and DY Ryoo. The Analysis of β-lactoglobulin and κ-casein cDNA in Korean Cattle and Holstein. Proceedings of the 8th Annual Congress of Animal Sciences and Technology, 1999.
130. Ryoo SH, BC Sang, SR Ryoo, TH Lee, S Lee and DY Ryoo. The Analysis of β-lactoglobulin and κ-casein gene promoter region in Korean Cattle and Holstein. Proceedings of the 8th Annual Congress of Animal Sciences and Technology, 1999.
131. Jin HJ, S Lee, HK Lee, MK Park, DS Son, MG Kim, TH Kim, BK Yang, JI Kim, BC Sang and SK Kim. Identification of Microsatellite for Economic Traits in Pig. Proceedings of the 8th Annual Congress of Animal Sciences and Technology:P99071, 1999.
132. Jeon BS, S Lee, CE Song, SB Choi, BS Ahn, JS Kim, DS Son, SH Ryoo, SK Kim and BC Sang. Association of the Resistance Gene for Bovine Leukemia Virus (BLV) in Bovine Lymphocyte Antigen DRB3 (BoLA-DRB3) with Milk Production traits in Holstein. Proceedings of the 8th Annual Congress of Animal Sciences and Technology:P99063, 1999.
133. Lee S, BC Sang, HB Kim, HS Kim, HJ Jin, SH Ryoo, SK Kim, YJ Park and KD Lee. The Genetic Characterization and Polymorphism of Growth Hormone Releasing Hormone (GHRH) Gene by Direct Sequencing Method in Cattle. Proceedings of the 8th Annual Congress of Animal Sciences and Technology:P99064, 1999.
134. Kim TH, DH Yoon, KS Seo, YK Lee, IC Cheong, SK Son and S Lee. Genetic characterization of pig breeds using microsatellite DNA markers. Proceedings of the 8th Annual Congress of Animal Sciences and Technology:P99014, 1998.
135. Ryoo SH, BC Sang, SW Han, S Lee, BS Jeon and JH Kim. Association of the genetic polymorphisms of κ-casein and β-lactoglobulin with preweaning body weights of Korean cattle using PCR-RFLP. The 8th World Conference on Animal Production Presentation:PG2-24, 1998.
136. Jin HY, CY Cho, HK Lee, HS Jang, S Lee, CH Choi, BD Sang, DS Son, YH Chung and Y Yamamoto. Analysis of Biochemical Genetic Polymorphisms in Korean Native Chicken and Foreign Breeds. The 8th World Conference on Animal Production Presentation:PG2-21, 1998.
137. Jin HJ, HK Lee, S Lee, SH Na, HS Kim, CY Cho, IS Ryoo, KJ Han and JI Kim. The Effect of Specific Genetic Markers on the Economic Traits of Bulls in Holstein. Proceedings of the 7th Annual Congress of Animal Sciences and Technology:PA97031, 1997.
138. Lee HK, HJ Jin, S Lee, TH Kim, SH Na, DW Lee, TY Heo, DS Son, JS Choi and MG Park. Study on the characterization of PSS (Porcine Stress Syndrome) gene expression. Proceedings of the 7th Annual Congress of Animal Sciences and Technology:A9717, 1997.
139. Ryoo SH, BC Sang, S Lee, HB Kang and CS Lee. Association between Genetic Polymorphism of Blood Protein and Meat Production Traits in Korean Native Goat. Proceedings of the 7th Annual Congress of Animal Sciences and Technology:A9711, 1997.
140. Lee S, HJ Jin, SH Na, CY Cho, KJ Jeon, HK Lee, KH Seo and JS Kim. The study on the characterization of genotypes of Specific gene in Korean Cattle and Holstein using PCR-RFLP. Proceedings of the 7th Annual Congress of Animal Sciences and Technology:A9713, 1997.
141. Lee S, BC Sang, I Kwon and CG Sung. The Analysis of Genetic Similarity between Korean cattle and Charolais using RAPD technique. Proceedings of the 6th Annual Congress of Animal Sciences and Technology:PA9614, 1996.
142. Lee S, BC Sang, SW Han, I Kwon and CG Sung. The Analysis of Genetic Diversity between Korean Cattle Meat and Imported Meat. Proceeding of the 57th Congress of Food Sciences:PA-25, 1996.
143. Choi IH, Lee S, Jang HJ, Lee CS, Sang BC, Oh HR. Verification of practicality of marker gene for identification of Korean cattle meatbeef. Korean Society for Food Science of Animal Resources:121, 1996. e-Pub 1996.